Skip to main content
SpringerLink
Log in

Generation of phenotypic diversity and progression in metastatic tumor cells

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The emergence of diversified tumor cell subpopulations in malignant neoplasms accounts for their heterogeneous cellular phenotypes and virtually ensures that some tumor cells will ultimately evolve with the most favorable properties for their enhanced abilities to survive, grow, invade and metastasize (tumor progression). The rates of cellular phenotypic diversification appear to vary greatly among different tumors and within the same tumor, and they are probably controlled, at least in part, by cellular instability due to chromosomal defects and random somatic mutational events, the rates of which are known to be higher in more malignant cells, and by epigenetic events, which may vary widely depending on the nature of the tumor cells and their microenvironments. As tumor progression proceeds, the most malignant cell subpopulations appear to lose their responsiveness to changes in tumor microenvironment while maintaining their high rates of phenotypic diversification.

Tumor and normal cell-cell and cell-extracellular matrix interactions, as well as tumor cell nutrients, oxygen, hormones, growth factors, inducers and other regulatory molecules provide individual malignant cells with microenvironmental signals that could act through epigenetic cellular modifications, such as DNA methylation, and transcriptional, posttranscriptional, translational and posttranslational controls, or combinations of these. In addition, integration of viral gene sequences or viral modification of host DNA in critical regions could affect phenotypic stability. Finally, manipulation of tumor cells by antitumor therapy can also have profound effects on the rates of phenotypic diversification of the surviving tumor cells.

A model for generating cellular phenotypic diversity based on the proposed mechanism for rapid generation of immunoglobulin molecular diversity in B cells may be applicable to malignant cells and to cells in general. In this model the expression and activity of gene products from multigene families are affected by a variety of genetic and epigenetic controlling mechanisms, and alterations in regulatory genes caused by recombination, methylation, mutation, or other changes could lead to differences in gene expression, resulting in widespread quantitative (and perhaps some qualitative) changes in particular gene products or their activities. As they proceed down different pathways of gene expression, each cell would be exposed to continual host selection pressures creating diverse, ever-changing malignant cell-populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fidler IJ, Nicolson GL: Immunobiology of experimental metastatic melanoma. Cancer Biol Rev (2): 171–234, 1981.

    Google Scholar 

  2. Hart IR, Fidler IJ: The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastasis. Biochim Biophys Acta (651): 37–50, 1981.

    Google Scholar 

  3. Nicolson GL: Cancer metastasis: Organ colonization and the cell surface properties of malignant cells. Biochim Biophys Acta (695): 113–176, 1982.

    Google Scholar 

  4. Poste G: Experimental systems for analysis of the malignant phenotype. Cancer Metastasis Rev (1): 141–199, 1982.

    Google Scholar 

  5. Nicolson GL, Poste G: Tumor cell diversity and host responses in cancer metastasis. I. Properties of metastatic cells. Curr Prob Cancer (7[6]): 1–83, 1982.

    Google Scholar 

  6. Nicolson GL, Poste G: Tumor cell diversity and host responses in cancer metastasis. H. Host immune responses and therapy of metastases. Curr Prob Cancer (7[7]): 1–43, 1983.

    Google Scholar 

  7. Fidler IJ, Hart IR: Biological diversity in metastatic neoplasms: origins and implications. Science (Wash) (217): 990–1003, 1982.

    Google Scholar 

  8. Nicolson GL, Poste G: Tumor implantation and invasion at metastatic sites. Int Rev Exp Pathol (25): 77–181, 1983.

    Google Scholar 

  9. Peterson JA, Ceriani RL, Blank EW, Osvaldo L: Comparison of rates of phenotypic variability in surface antigen expression in normal and cancerous breast epithelial cells. Cancer Res (43): 4291–4296, 1983.

    Google Scholar 

  10. Peterson JA, Bartholomew JC, Stampfer M, Ceriani RL: Analysis of expression of human mammary epithelial antigens in normal and malignant breast cells at the single cell level by flow cytofluorimetry. Exp Cell Biol (49): 1–14, 1981.

    Google Scholar 

  11. Griffin JE, Allman DR, Durant JL, Wilson JD: Variation in steroid 5-α-reductase activity in cloned skin fibroblasts. J Biol Chem (256): 3662–3666, 1981.

    Google Scholar 

  12. Fialkow PJ, Gartier SM, Yoshida A: Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA (58): 1468–1471, 1967.

    Google Scholar 

  13. Fialkow PJ: Clonal origin of human tumors. Ann Rev Med (30): 135–176, 1979.

    Google Scholar 

  14. Chaganti RSK: The significance of chromosome change to neoplastic development. In: German J (ed) Chromosome mutation and neoplasia. AR Liss, Inc, New York, 1983, pp 359–396.

    Google Scholar 

  15. Nowell PC: The clonal evolution of tumor cell populations. Science (Wash) (194): 23–28, 1976.

    Google Scholar 

  16. Foulds L: Neoplastic development. Academic Press, New York, 1975.

    Google Scholar 

  17. Foulds L: The histologic analysis of mammary tumors of mice. I. Scope of investigations and general principles of analysis. J Natl Cancer Inst (17): 701–712, 1956.

    Google Scholar 

  18. Foulds L: The histologic analysis of mammary tumors of mice. II. The histology of responsivesness and progression. The origin of tumors. J Natl Cancer Inst (17): 713–754, 1956.

    Google Scholar 

  19. Nowell PC: tumor progression and clonal evolution: The role of genetic instability. In: German J (ed) Chromosome mutation and neoplasia. AR Liss, Inc, New York, 1983, pp 413–432.

    Google Scholar 

  20. Wolman SR: Karyotypic progression in human tumors. Cancer Met Rev (2): 257–293, 1983.

    Google Scholar 

  21. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science (132): 1497, 1960.

    Google Scholar 

  22. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by Quinacrin fluorescence and Giemsa staining. Nature (London) (243): 290–293, 1973.

    Google Scholar 

  23. Rowley JD: Nonrandom chromosomal abnormalities in hematologic disorders of man. Proc Natl Acad Sci (72): 152–156, 1975.

    Google Scholar 

  24. Mitelman F: The Rous sarcoma virus story: Cytogenetics of tumor induced by RSV. In: German J (ed) Chromosomes and cancer. J Wiley and Sons, New York, 1974, pp 675–693.

    Google Scholar 

  25. Pearce V, Pathak S, Mellard D, Welch DR, Nicolson GL: Chromosome and DNA analysis of rat 13762NF mammary adenocarcinoma cell lines and clones of different metastatic potentials. Cancer Res, 1983 (submitted).

  26. Barlogie B, Johnston DA, Smallwood L: Prognostic implications of ploidy and proliferative activity in human solid tumors. Cancer Genet Cytogenet (6): 17–28, 1982.

    Google Scholar 

  27. Olszewski W, Darzynkiewicz Z, Rosen PP, Schwartz MK, Melamed MR: Flow cytometry of breast carcinoma. I. Relation of DNA ploidy level to histology and estrogen receptor. Cancer (48): 980–984, 1981.

    Google Scholar 

  28. Auer GV, Casperson TO, Gustafsson SA, Humia SA, Ljung MB, Nordenskjold BA, Silversward D, Wallgren AS: Relationship between nuclear DNA distribution and estrogen receptors in human mammary carcinomas. Ann Quant Cytol (2): 280–284, 1980.

    Google Scholar 

  29. Kusyk J, Seski JC, Medlin V, Edwards CL: Progressive chromosome changes associated with different sites of one ovarion carcinoma. J Natl Cancer Inst (66): 1021–1025, 1981.

    Google Scholar 

  30. Testa JR, Mintz U, Rowley JE, Vardiman JW, Golomb HM: Evolution of karyotypes in active nonlymphocytic leukemia. Cancer Res (39): 3619–3627, 1979.

    Google Scholar 

  31. Goldberg S, Defendi V: Increased mutation rates in doubly viral transformed Chinese hamster cells. Somatic Cell Genet (5): 887–895, 1979.

    Google Scholar 

  32. Cifone MA, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA (78): 6949–6952, 1981.

    Google Scholar 

  33. Cooper GM: Cellular transforming genes. Science (218): 801–806, 1982.

    Google Scholar 

  34. Blair DG, Oskarsson M, Wood TG, McClements WL, Fischinger PJ, Van de Woude G: Activation of the tranforming potential of a normal cell sequence: A molecular model for oncogenesis. Science (Wash) (212): 941–943, 1981.

    Google Scholar 

  35. DeFeo D, Gonda MA, Young HA, Chang EH, Lowy DR, Scolnick E, Ellis RW: Analysis of divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci USA (78): 3328–3332, 1981.

    Google Scholar 

  36. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene promoter insertion in ALV-induced lymphoid leukosis. Nature (London) (290): 475–480.

  37. Schwab M, Alitalo K, Varmus HE, Bishop JM, George D. A cellular oncogene (c-Kiras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (London) (303): 497–501, 1983.

    Google Scholar 

  38. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines, and a neuroblastoma tumour. Nature (London) (305): 245–248, 1983.

    Google Scholar 

  39. Holliday RA: A new theory of carcinogenesis. Brit J Cancer (40): 513–522, 1979.

    Google Scholar 

  40. Nicolson GL: Cell surface molecules and tumor metastasis. Regulation of metastatic diversity. Exp Cell Res (150): 3–22, 1984.

    Google Scholar 

  41. Poste G, Doll J, Fidler IJ: Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci USA (78): 6226–6230, 1981.

    Google Scholar 

  42. Klein G, Klein E: Conversion of solid neoplasma into ascites tumors. Ann NY Acad Sci (63): 640–661, 1956.

    Google Scholar 

  43. Miner KM, Kawaguchi T, Uba GW, Nicolson GL: Clonal drift of cell surface, melanogenic and experimental metastatic properties of in vivo-selected, brain meninges-colonizing murine B16 melanoma. Cancer Res (42): 4631–4638, 1982.

    Google Scholar 

  44. Miller BE, Miller GR, Leith J, Heppner GH: Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res (40): 3977–3981, 1980.

    Google Scholar 

  45. Miller BE, Miller FR, Heppner GH: Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res (41): 4378–4381, 1981.

    Google Scholar 

  46. Nicolson GL, Mascali JJ, McGuire EJ: Metastatic RAW117 lymphosarcoma as a model for malignant-normal cell interactions. Possible roles for cell surface antigens in determining the quantity and location of secondary tumors. Oncodevelop Biol Med (4): 149–159, 1982.

    Google Scholar 

  47. Kerbel RS, Roder JC, Pross HF: Induction of malignant lymphoreticular cell line which displays spontaneous killer-cell activity. Int J Cancer (27): 87–94, 1981.

    Google Scholar 

  48. Poste G, Tzeng J, Doll J, Greig R, Rieman D, Zeidman I: Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci USA (79): 6574–6578, 1982.

    Google Scholar 

  49. Neri A, Nicolson GL: Phenotypic drift of metastatic and cell surface properties of mammary adenocarcinoma cell clones during growth in vitro. Int J Cancer (28): 731–738, 1981.

    Google Scholar 

  50. Neri A, Welch D, Kawaguchi T, Nicolson GL: The development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst (68): 507–517, 1982.

    Google Scholar 

  51. Welch DR, Neri A, Nicolson GL: Comparison of ‘spontaneous’ and ‘experimental’ metastasis using rat 13762 mammary adenocarcinoma metastatic cell clones. Invasion Metastasis (3): 65–80, 1983.

    Google Scholar 

  52. Steck PA, Nicolson GL: Cell surface glycoproteins of 13762NF mammary adenocarcinoma clones of differing metastatic potentials. Exp Cell Res (147): 255–267, 1983.

    Google Scholar 

  53. Neri A, Ruoslahti E, Nicolson GL: Distribution of fibronectin on clonal cell lines of a rat mammary adenocarcinoma growing in vitro and in vivo at primary and metastatic sites. Cancer Res (41): 5082–5095, 1981.

    Google Scholar 

  54. Welch DR, Milas L, Tomasovic SP, Nicolson GL: Heterogeneous response and clonal drift of sensitivities of metastatic 13762NF mammary adenocarcinoma clones to gamma radiation in vitro. Cancer Res (43): 6–10, 1983.

  55. Tomasovic SP, Thames HD Jr, Nicolson GL: Heterogeneity in hyperthermic sensitivities of rat 13762NF mammary adenocarcinoma cell clones of differing metastatic potentials. Radiat Res (91): 555–563, 1982.

    Google Scholar 

  56. Welch DR, Nicolson GL: Phenotypic drift and heterogeneity in response of metastatic mammary adenocarcinoma cell clones to adriamycin, 5-fluoro-2′-deoxyuridine and methotrexate treatment in vitro. Clin Exp Metastasis (1): 317–325, 1983.

  57. Raz A: Clonal emergence of metastatic heterogeneity in a growing tumor. Cancer Lett (17): 153–160, 1982.

    Google Scholar 

  58. Nicolson GL, Steck PA, Welch DR, Lembo T: Heterogeneity and instability of phenotypic and metastatic properties of local tumor- and metastasis-derived clones of a mammary adenocarcinoma. In: Rich M, Hager J, Furmanski P (eds) Understanding breast cancer: Clinical and laboratory concepts. M Dekker, Inc, New York, 1983, pp 145–166.

    Google Scholar 

  59. Kerbel RS: Immunologic studies of membrane mutants of a highly metastatic murine tumor. Am J Pathol (97): 609–622, 1979.

    Google Scholar 

  60. Dennis JW, Donaghue TP, Kerbel RS: An examination of tumor antigen loss in spontaneous metastasis. Invasion Metastasis (1): 111–125, 1981.

    Google Scholar 

  61. Lagarde AE: A flunctuation analysis of the rate of reexpression of the metastatic potential in a nonmetastatic mutant of the MDAY-D2 murine tumor. Invasion Metastasis (3): 52–64, 1983.

    Google Scholar 

  62. Chow DA, Greenberg AH: The generation of tumor heterogeneity in vivo. Int J Cancer (25): 261–265, 1980.

    Google Scholar 

  63. Talmadge JE, Starkey JR, Davis WC, Cohen AL: Introduction of metastatic heterogeneity by short-term in vivo passage of a cloned transformed cell line. J Supramol Struct (12): 227–243, 1979.

    Google Scholar 

  64. Bosslet K, Schirrmacher V: High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). Int J Cancer (29): 195–202, 1982.

    Google Scholar 

  65. Harris JF, Chambers AF, Hill RP, Ling V: Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proc Natl Acad Sci USA (79): 5547–5551, 1982.

    Google Scholar 

  66. Stackpole CW: Generation of phenotypic diversity in the B16 mouse melanoma relative to spontaneous metastasis. Cancer Res (43): 3057–3065, 1983.

    Google Scholar 

  67. Schirrmacher V: Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis. Immunobiol (157): 89–98, 1980.

    Google Scholar 

  68. Poste G, Grieg R, Tzeng J, Koestler T, Corwin S: Interactions between tumor-cell subpopulations in malignant tumors. In: Nicolson GL, Milas L (eds) Cancer invasion and metastasis: Biologic and therapeutic aspects, Raven Press, New York, 1984, pp 223–243.

    Google Scholar 

  69. Goldenberg DM, Pavia RA, Tsao MC: in vivo hybridization of human tumor and normal hamster cells. Nature (London) (250): 649–651, 1974.

    Google Scholar 

  70. Hu F, Pasztor LM: In vivo hybridization of cultured melanoma cells and isogeneic normal mouse cells. Differentiation (4): 92–97, 1975.

    Google Scholar 

  71. DeBaetselier P, Gorelik E, Eshhar Z, Ron Y, Katzav S, Feldman M, Segal S: Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen B-lymphocytes with plasmocytoma cells. J Natl Cancer Inst (67): 1079–1087, 1981.

    Google Scholar 

  72. Lagarde AE, Donaghue TP, Dennis JW, Kerbel RS: Genotypic and phenotypic evolution of a murine tumor during its progression in vivo toward metastasis. J Natl Cancer Inst (71): 183–191, 1983.

    Google Scholar 

  73. Revesz L, Norman L: Relationship between chromosome ploidy and radiosensitivity in selected tumor sublines of common origin. J Natl Cancer Inst (25): 1041–1063, 1960.

    Google Scholar 

  74. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (38): 3174–3181, 1978.

    Google Scholar 

  75. Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P: Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res (38): 3758–3763, 1978.

    Google Scholar 

  76. Nicolson GL, Lotan R, Rios A: Heterogeneous in vitro sensitivities of metastatic B16 melanoma sublines and clones to retinoic acid or BCNU. Cancer Treat Rep (65, Suppl 2), 71–74, 1982.

    Google Scholar 

  77. Barranco SC, Ho DHW, Drewinko B, Romsdahl MM, Humphrey RM: Differential sensitivities of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res (32): 2733–2736, 1972.

    Google Scholar 

  78. Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Res (41): 3058–3064, 1981.

    Google Scholar 

  79. Lotan R, Nicolson GL: Heterogeneity in growth inhibition by β-trans-retinoic acid of metastatic B16 melanoma clones and in vivo-selected cell variant lines. Cancer Res (39): 4767–4771, 1979.

    Google Scholar 

  80. Lotan R: Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res (39): 1014–1019, 1979.

    Google Scholar 

  81. Brenman MJ, Donegan WL, Appleby DE: The variability of estrogen receptors in metastatic breast cancer. Am J Surg (137): 260–262, 1979.

    Google Scholar 

  82. Sluyser M, Van Nie R: Estrogen receptor content and hormone-responsive growth of mouse mammary tumors. Cancer Res (34): 3253–3257, 1974.

    Google Scholar 

  83. Baylin SB, Weisburger WR, Eggleston JC, Mendelsohn G, Bearnen MA, Abelhoff MD, Ettinger DS: Variable content of histaminase, L-dope decarboxylase and calcitonin in small-cell carcinoma of the lung. New Engl J Med (299): 105–110, 1978.

    Google Scholar 

  84. Kim U: Metastasizing mammary carcinomas in rats: Induction and study of their immunogenicity. Science (Wash) (164): 72–74, 1970.

    Google Scholar 

  85. Kim U, Baumler A, Carruthers C, Bielat K: Immunological escape mechanism in spontaneously metastasizing mammary tumors. Proc Natl Acad Sci USA (72): 1012–1016, 1975.

    Google Scholar 

  86. Fidler IJ, Gersten DM, Kripke ML: The influence of immunity on the metastasis of three murine fibrosarcomas of differing immunogenicity. Cancer Res (39): 3816–3821, 1979.

    Google Scholar 

  87. Olsson L, Ebbeson P: Natural polyclonality of spontaneous AKR leukemia and its consequences for socalled specific immunotherapy. J Natl Cancer Inst (62): 623–627.

  88. Sugarbaker EV, Cohen AM, Ketcham AS: Concomitant tumor immunity and immunoselection of metastases. Curr Top Surg (3): 349–358, 1971.

    Google Scholar 

  89. Sugarbaker EV, Cohen AM: Altered antigenicity in spontaneous pulmonary metastases from an antigenic murine sarcoma. Surgery (72): 155–161, 1972.

    Google Scholar 

  90. Kerbel RS, Twiddy RR, Robertson DM: Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer (22): 583–594, 1978.

    Google Scholar 

  91. Pimm MV, Baldwin RW: Antigenic differences between primary methylcholanthrene-induced rat sarcoma and post-surgical recurrences. Int J Cancer (20): 37–43, 1977.

    Google Scholar 

  92. Reading CL, Brunson KW, Torrianni M, Nicolson GL: Malignancies of metastatic murine lymphosarcoma cell lines and clones correlated with decreased cell surface display of RNA tumor virus envelope glycoprotein gp70. Proc Natl Acad Sci USA (77): 5943–5947, 1980.

    Google Scholar 

  93. Gorelik E, Fogel M, Feldman M, Segal S: Differences in resistance of metastatic tumor cells and cells from local tumor growth to cytotoxicity of natural killer cells. J Natl Cancer Inst (63): 1397–1404, 1979.

    Google Scholar 

  94. Gorelik E, Feldman M, Segal S: Selection of a 3LL tumor subline resistant to natural effector cells concomitantly selected for increased metastatic potency. Cancer Immunol Immunother (12): 105–109, 1982.

    Google Scholar 

  95. Hanna N, Fidler IJ: Expression of metastatic potential of allogenic and xenogenetic neoplasms in young nude mice. Cancer Res (42): 438–444, 1981.

    Google Scholar 

  96. Miller FR, Heppner GH: Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst (63): 1457–1463, 1979.

    Google Scholar 

  97. Schirrmacher V, Bosslet K: Clonal analysis of expression of tumor associated transplantation antigens and of metastatic capacity. Cancer Immunol Immunother (13): 62–68, 1982.

    Google Scholar 

  98. Miner KM, Klostergaard J, Granger GA, Nicolson GL: Differences in the cytotoxic effects of activated peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma. J Natl Cancer Inst (70): 717–724, 1983.

    Google Scholar 

  99. Miner KM, Nicolson GL: Differences in the sensitivities of murine metastatic lymphoma/lymphosarcoma cells to macrophage-mediated cytolysis and/or cytostatis. Cancer Res (43): 2063–2071, 1983.

    Google Scholar 

  100. Goldin A, Johnson RK: Resistance to antitumor agents. In: Tagnon HJ, Staquet MJ (eds) Recent advances in cancer treatment. Raven Press, New York, 1977 pp 155–169.

    Google Scholar 

  101. Slack NH, Bross IDJ: The influence of site of metastasis on tumour growth and response to chemotherapy. Br J Cancer (32): 78–86, 1975.

    Google Scholar 

  102. Fugmann RA, Anderson JC, Stolf RL, Martin DS: Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. Cancer Res (57): 496–500, 1977.

    Google Scholar 

  103. Kerbel RS, Frost P, Liteplo R, Carlow D, Elliott BE: Possible epigenetic mechanisms of tumor progression: Induction of high frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol, 1984, (in press).

  104. Frost P, Kerbel RS: On the possible epigenetic mechanisms(s) of tumor cell heterogeneity. Cancer Metastasis Rev (2): 375–378, 1983.

    Google Scholar 

  105. Razin A, Riggs A: DNA methylation and gene function. Science (210): 604–610, 1980.

    Google Scholar 

  106. Christman JK, Price P, Pedainan L, Acs G: Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur J Biochem (81): 53–59, 1977.

    Google Scholar 

  107. Jones PD, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell (2): 85–93, 1980.

    Google Scholar 

  108. Feinberg A, Vogelstein Bij Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (London) (301): 89–92, 1983.

    Google Scholar 

  109. Brown DD: Gene expression in eukaryotes. Science (211): 667–674, 1981.

    Google Scholar 

  110. Darnell JE Jr: Variety in the level of gene control in eukaryotic cells. Nature (London) (297): 365–371, 1982.

    Google Scholar 

  111. Bissell MJ, Hall HG, Parry G: How does the extracellular matrix direct gene expression? J Theoret Biol (99): 31–68, 1982.

    Google Scholar 

  112. Saxen L, Karkinen-Jaaskelainen M, Lehtonen E, Nordling S, Wartiovaara J: Inductive tissue interactions in the cell surface in animal embryogenesis and development. In: Poste G, Nicolson GL (eds) The cell surface in animal embryogenesis and development. Vol 1. Cell surface reviews. Nort Holland, New York, 1976, pp 331–407.

    Google Scholar 

  113. Sachs L: Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia: A model for the origin and progression of malignancy. Proc Natl Acad Sci USA (77): 6152–6156, 1980.

    Google Scholar 

  114. Metcalf D: Studies on colony formation in vitro by mouse bone marrow cells. I. Continuous cluster formation and relation of clusters to colonies. J Cell Physiol (74): 323–332, 1969.

    Google Scholar 

  115. Landau T, Sachs L: Characterization of the inducer required for the development of macrophage and granulocyte colonies. Proc Natl Acad Sci USA (68): 2540–2544, 1971.

    Google Scholar 

  116. Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA (72): 3585–3589, 1975.

    Google Scholar 

  117. Heppner GH, Loveless SE, Miller FR, Mahoney KH, Fulton AM: Mammary tumor heterogeneity. In: Nicolson GL, Milas L (eds) Cancer invasion and metastasis: biologic and therapeutic aspects. Raven Press, New York, 1984, pp 209–221.

    Google Scholar 

  118. Hood L, Loh E, Hubert J, Barstad P, Eaton B, Early P, Fuhrman J, Johnson N, Kronenberg M, Schilling J: The structure and genetics of mouse immunoglobulins: An analysis of NZB myeloma proteins and sets of BALB/c myeloma proteins binding particular haptens. Cold Spring Harbor Symp Quant Biol (41): 817–836, 1977.

    Google Scholar 

  119. Hood L, Huang HV, Dreyer WJ: The area-code hypothesis: The immune system provides clues to understanding the genetic and molecular basis of cell recognition during development. J Supramol Struct (7): 531–559, 1977.

    Google Scholar 

  120. Tonegawa S, Hozumi N, Matthyssens G, Schuller R: Somatic changes in the content and context of immunoglobulin genes. Cold Spring Harbor Symp Quant Biol (41): 877–889, 1977.

    Google Scholar 

  121. Tonegawa S: Somatic generation of antibody diversity. Nature (London) (302): 575–581, 1983.

    Google Scholar 

  122. Klein G: Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and man. Cell (32): 311–315, 1983.

    Google Scholar 

  123. Perry RP: Consequences of myc invasion of immunoglobulin loci: facts and speculation. Cell (33): 647–649, 1983.

    Google Scholar 

  124. Chaganti RSK, Jhanwar SC: Oncogenes, chromosome mutation and the development of neoplasia. In: German J (ed) Chromosome mutation and neoplasia. Alan R. Liss, New York, 1983, pp 397–412.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Tumor Biology, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, 77030, Houston, TX, USA

    Garth L. Nicolson

Authors
  1. Garth L. Nicolson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nicolson, G.L. Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metast Rev 3, 25–42 (1984). https://doi.org/10.1007/BF00047691

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00047691

Keywords

Search

Navigation